Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 11/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | BCL6 | P41182 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448417 | 0.93 | RAF1 (0.36) | RAF1BRAFSYKCSNK2A1CSNK1A1 | |
| SCHEMBL3450205 | 0.91 | SYK (0.37) | RAF1BRAFSYKBCL6 | |
| SCHEMBL3449417 | 0.91 | SYK (0.38) | SYKCSNK2A1 | |
| SCHEMBL3448252 | 0.90 | CSNK2A1 (0.37) | SYKCSNK2A1RIPK2NOD2 | |
| SCHEMBL3447298 | 0.90 | RAF1 (0.38) | RAF1BRAFSYKCSNK2A1 | |
| SCHEMBL3450229 | 0.89 | SYK (0.39) | RAF1BRAFSYKCSNK2A1BCL6 | |
| SCHEMBL3450088 | 0.87 | SYK (0.40) | BRAFSYKMAP3K8 | |
| SCHEMBL3447552 | 0.86 | RAF1 (0.38) | RAF1BRAFSYK | |
| SCHEMBL3450256 | 0.86 | EGFR (0.37) | SYK | |
| SCHEMBL13312614 | 0.84 | SYK (0.35) | SYKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | RAF1 2448/4885BRAF 1251/4885SYK 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.